CHICAGO, Oct. 14, 2016 /PRNewswire/ -- The Boeing
(NYSE: BA) board of directors has elected Robert A. Bradway as a new member.
Bradway, 53, is chairman and CEO of Amgen, one of the world's
leading biotechnology companies.
Bradway joined Amgen in 2006 and has served the company in
senior finance and operations strategy roles, including chief
financial officer and chief operating officer. He was elected CEO
in 2012 and chairman in 2013. He joined Amgen from Morgan Stanley
where he had responsibility for the firm's banking department and
corporate finance activities in Europe.
"Bob brings to the Boeing board a global perspective from a
company making long-term investments in an advanced high-technology
and innovation-focused industry," said Boeing Chairman, President
and CEO Dennis Muilenburg. "His
accomplishments in business, operations and finance will serve
Boeing well as he applies his broad-based experience to
aerospace."
Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business
administration from Harvard University.
He is a member of the board of directors of Norfolk Southern
Corporation and serves on the board of trustees of the University of Southern California. He is chairman
of the CEO Roundtable on Cancer, a non-profit organization
comprised of executives founded to bring solutions to cancer
treatment and prevention.
He will serve on the Boeing board's Audit and Finance
committees.
Contact:
John Dern,
Boeing Communications
+1 312-544-2002
john.dern@boeing.com
Follow us on Twitter: @Boeing
Photo - http://photos.prnewswire.com/prnh/20161014/428796
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boeing-board-elects-amgen-ceo-bradway-as-new-director-300345117.html
SOURCE Boeing